Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia

Biomedicine and Pharmacotherapy

Volumn 63, Issue 8, 2009, Pages 566-570

  Li, Guang Yao ^a   Liu, Ji Zhu ^a   Zhang, Bin ^a   Wang, Le Xin ^b   Wang, Chun Bo ^c   Chen, Shou Guo ^d  

^a LIAOCHENG PEOPLE'S HOSPITAL   (China)

^b CHARLES STURT UNIVERSITY   (Australia)

^c QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^d Haisheng Oncology Hospital of Qingdao   (China)

Author keywords

Acute myeloid leukemia; Cancer; Cyclosporin A; Leukemia; Multidrug resistance

Indexed keywords

CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; IDARUBICIN; RHODAMINE 123; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN K 562; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL TRANSPORT; CELL SURVIVAL; CYCLOSPORINE; CYTARABINE; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT DYES; HUMANS; IDARUBICIN; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MALE; P-GLYCOPROTEIN; RHODAMINE 123; TIME FACTORS; TREATMENT OUTCOME; VERAPAMIL;

EID: 70349326661     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.10.008     Document Type: Article

References (15)

1. Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89 (1997) 3323-3329
2. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94 (1999) 1086-1099
3. Abd El-Ghaffar H.A., Aladle D.A., Farahat S.E., and Abd El-Hady N. P-glycoprotein (P-170) expression in acute leukemias. Hematology 11 (2006) 35-41
4. Nooter K., Sonneveld P., Oostrum R., Herweijer H., Hagenbeek T., and Valerio D. Overexpression of the MDRL gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer 45 (1990) 263-268
5. Qadir M., O'Loughlin K.L., Fricke S.M., Williamson N.A., Greco W.R., Minderman H., et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11 (2005) 2320-2326
6. Smeets M., Raymakers R., Muus P., Vierwinden G., Linssen P., Masereeuw R., et al. Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance. Leukemia 15 (2001) 80-88
7. Knaust E., Porwit-MacDonald A., Gruber A., Xu D., and Peterson C. Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML. Leuk Res 27 (2003) 183-191
8. McGahon A.J., Martin S.J., Bissonnette R.P., Mahboubi A., Shi Y., Mogil R.J., et al. The end of the (cell) line: methods for the study of apoptosis in vitro. In: Schwartz L.M., and Osborne B.A. (Eds). Cell death vol. 46 (1995), Academic Press, San Diego, CA 153-185
9. Mahadevan D., and List A.F. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 104 (2004) 1940-1951
10. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95 (1998) 15665-15670
11. Altenberg G.A., Vanoye C.G., Horton J.K., and Reuss L. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc Natl Acad Sci USA 24 (1994) 4654-4657
12. Ito C., Ribeiro R.C., Behm F.G., Raimondi S.C., Pui C.H., and Campana D. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood 91 (1998) 1001-1007
13. Liu Yin J.A., Wheatley K., Rees J.K., and Burnett A.K. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 113 (2001) 713-726
14. List A.F., Kopecky K.J., Willman C.L., Head D.R., Persons D.L., Slovak M.L., et al. Benefitof cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98 (2001) 3212-3220
15. Becton D., Dahl G.V., Ravindranath Y., Chang M.N., Behm F.G., Raimondi S.C., et al., Pediatric Oncology Group. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 107 (2006) 1315-1324